Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02717611
Title A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications
Therapies
Age Groups: adult
Covered Countries USA | FRA | ESP | BEL


No variant requirements are available.